Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIREFLY-2 first-line tovorafenib versus standard chemotherapy in pediatric low-grade glioma with RAF alteration
2022-001363-27Phase 3Active
- Sponsor
- Day One Biopharmaceuticals
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in childhood low-grade glioma (pLGG) and glioma comparing Tovorafenib monotherapy with Standard-of-care chemotherapy (2 arms). Primary endpoint: Objective response rate. Started Oct 2022; status: active.
02
Drugs
tovorafenib
03
Conditions
childhood low-grade glioma (pLGG)glioma
Beyond the preview
Go deeper on 2022-001363-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001363-27.